Siolta - Model STMC-106 - Prevention of Necrotize Entercolitis (NEC)
Necrotizing enterocolitis is a serious inflammatory disease of the bowel and the most common single cause of sepsis and death in preterm infants. NEC occurs primarily in infants born before 32 weeks gestation, with overall incidence inversely proportional to gestational age. Several additional risk factors for NEC, including initiation of enteral feeding, antibiotic treatment, and acid suppression treatment, are key factors influencing the development of the preterm infant gut microbiome.
Product Details
Observations of abnormal infant gut microbiome development in preterm infants, with increased colonization by opportunistic pathobionts, strongly supports the role of the gut microbiome in the pathogenesis of NEC. Siolta Therapeutics is leveraging our proprietary Precision Symbiotic Platform to develop STMC-106, a mixed-species LBP designed to fortify the preterm infant gut by instilling protective microbe-epithelial signaling and metabolic activity that reduces pathobiont colonization and restores intestinal epithelial barrier function. STMC-106 will simultaneously leverage multiple mechanisms of action to reduce the development of NEC in high-risk preterm infants.
Customer reviews
No reviews were found for Siolta - Model STMC-106 - Prevention of Necrotize Entercolitis (NEC). Be the first to review!